Your browser doesn't support javascript.
loading
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat, Aleix; Saura, Cristina; Pascual, Tomás; Hernando, Cristina; Muñoz, Montserrat; Paré, Laia; González Farré, Blanca; Fernández, Pedro L; Galván, Patricia; Chic, Núria; González Farré, Xavier; Oliveira, Mafalda; Gil-Gil, Miguel; Arumi, Miriam; Ferrer, Neus; Montaño, Alvaro; Izarzugaza, Yann; Llombart-Cussac, Antonio; Bratos, Raquel; González Santiago, Santiago; Martínez, Eduardo; Hoyos, Sergio; Rojas, Beatriz; Virizuela, Juan Antonio; Ortega, Vanesa; López, Rafael; Céliz, Pamela; Ciruelos, Eva; Villagrasa, Patricia; Gavilá, Joaquín.
Afiliação
  • Prat A; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. Electronic address: alprat@clini
  • Saura C; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Pascual T; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Hernando C; Department of Medical Oncology, Hospital Clínico Universitario of Valencia, Valencia, Spain.
  • Muñoz M; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Paré L; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • González Farré B; Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Fernández PL; Department of Pathology, Hospital Germans Trials i Pujol, Badalona, Spain.
  • Galván P; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • Chic N; SOLTI Breast Cancer Research Group, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
  • González Farré X; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital General de Catalunya, Barcelona, Spain.
  • Oliveira M; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Gil-Gil M; Department of Medical Oncology, Institut Català d'Oncologia Hospitalet, Hospitalet de Llobregat, Spain.
  • Arumi M; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Ferrer N; Department of Medical Oncology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
  • Montaño A; Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Izarzugaza Y; Department of Medical Oncology, Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain.
  • Llombart-Cussac A; Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain.
  • Bratos R; Department of Medical Oncology, Centro Oncológico Internacional MD Anderson, Madrid, Spain.
  • González Santiago S; Department of Medical Oncology, Hospital San Pedro de Alcántara, Cáceres, Spain.
  • Martínez E; Department of Medical Oncology, Consorcio Hospitalario Provincial of Castellón, Castellón de la Plana, Spain.
  • Hoyos S; Department of Medical Oncology, Hospital Rey Juan Carlos, Madrid, Spain.
  • Rojas B; Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Madrid, Spain.
  • Virizuela JA; Department of Medical Oncology, Hospital Virgen de la Macarena, Sevilla, Spain.
  • Ortega V; Department of Medical Oncology, Fundación Privada Asil de Granollers, Barcelona, Spain.
  • López R; Department of Medical Oncology, Complejo Universitario de Santiago de Compostela, Spain.
  • Céliz P; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Ciruelos E; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain.
  • Villagrasa P; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Gavilá J; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain.
Lancet Oncol ; 21(1): 33-43, 2020 01.
Article em En | MEDLINE | ID: mdl-31838010
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Progesterona / Receptores de Estrogênio / Carcinoma Lobular / Carcinoma Ductal de Mama / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Progesterona / Receptores de Estrogênio / Carcinoma Lobular / Carcinoma Ductal de Mama / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article